TICKERNERD
Menu
PHIOPHIOHealthcare · Biotechnology

PHIO Stock Forecast: Phio Pharmaceuticals Corp. Price Predictions for 2026-2027

Last close, 13 Oct 2026
$0.93
+1.36% on the day

The 1 Wall Street analysts covering Phio Pharmaceuticals Corp. hold a median 12-month price target of $14 — +1398.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 15 of 100 as at 13 Oct 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$10.8M
Ticker Nerd rank
15 / 100
Median analyst target
$14
Analysts covering
1
Revenue$0.0
Operating income−$4.3M
Net income−$4.1M
Free cash flow−$4.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−6.0%
1M
−9.3%
YTD
−11.0%
1Y
−57.1%
From 52W high
−58.3%
From 52W low
+9.0%
$0.86
$2.24
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

PHIO stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Phio Pharmaceuticals Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 13 Oct 2026
15 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
91
Volatility
47
Quality
46
Accruals
44
Revisions
25
Issuance
25
Growth
25
Value
12
Momentum
5

Size (91): Smaller than most of the companies we track.

Momentum (5): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

PHIO stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PHIO, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00Jan 26Apr 26Jul 26Oct 26PHIOHigh $14Median $14Low $14

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Low $14Median $14High $14

The green dot is the last close — the median target sits +1398.1% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
26 Aug 2026HC Wainwright & Co.ReiteratesBuy$14
10 Feb 2026HC Wainwright & Co.ReiteratesBuy$14
10 Feb 2026HC Wainwright & Co.ReiteratesBuy—
15 Aug 2025HC Wainwright & Co.ReiteratesBuy—
25 June 2025HC Wainwright & Co.ReiteratesBuy—
5 June 2025HC Wainwright & Co.AssumesBuy$14
8 Apr 2025HC Wainwright & Co.ReiteratesBuy—
19 Feb 2025HC Wainwright & Co.ReiteratesBuy—
14 May 2024HC Wainwright & Co.ReiteratesBuy—
6 Feb 2024HC Wainwright & Co.MaintainsBuy—
16 Aug 2023HC Wainwright & Co.ReiteratesBuy—
14 June 2021HC Wainwright & Co.MaintainsBuy$4.00 → $6.00
25 Nov 2020HC Wainwright & Co.InitiatesBuy—
5 Aug 2020HC Wainwright & Co.InitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PHIO appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

PHIO vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 13 Oct 2026, Phio Pharmaceuticals Corp. returned −57.1% against +18.6% for the S&P 500, dividends included.

PHIO vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120Jan 26Apr 26Jul 26Oct 26PHIOS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

PHIO analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
2
Fundamentals

Phio Pharmaceuticals Corp. (PHIO) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.0×

Cheaper than 74% of US stocks

Price / sales
—
Price / book
0.9×

Cheaper than 75% of US stocks

EV / EBITDA
0.2×

Cheaper than 60% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−113.7%

Higher than 12% of US stocks

Return on assets
−65.8%

Higher than 5% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Phio Pharmaceuticals Corp. (PHIO) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Phio Pharmaceuticals Corp. has a market value of $10.8M and an enterprise value of −$2.3M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$12.9M.

  • Free cash flow in the twelve months to 30 June 2026: −$12.2M.

  • Shares outstanding: 11.6M.

  • Trailing P/E: 0.0×; forward P/E: −1.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Phio Pharmaceuticals Corp. employs 6 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Oct 2026

Data provided by Twelve Data

Peers

PHIO vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
PHIOPhio Pharmaceuticals Corp.$10.8M
15
KPRXKiora Pharmaceuticals, Inc.$10.9M
76
LTRNLantern Pharma, Inc.$10.6M
45
ENSCEnsysce Biosciences, Inc.$11.1M
32
ACTUActuate Therapeutics, Inc.$11.2M
34
GDTCCytoMed Therapeutics Ltd.$10.3M
30
AEONAEON Biopharma, Inc.$11.5M
51

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Phio Pharmaceuticals Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest PHIO news & analysis

Phio Pharmaceuticals to Present at the National Investment Banking Association (NIBA) 153rd Conference

Newsfile Corp · 5 Oct 2026neutral

Phio Pharmaceuticals announced it will present at the National Investment Banking Association's 153rd Conference on October 6-7, 2026, in Fort Lauderdale, Florida. CEO Robert Bitterman will present the company's INTASYL siRNA therapeutic platform, its differentiated delivery approach, and its strategic direction, including a development update on the lead PH-762 program in cutaneous squamous cell carcinoma.

Why it matters — The presentation offers PHIO watchers a scheduled opportunity to hear directly from management about the company's lead PH-762 program and strategic direction at a national investor event.

Phio Pharmaceuticals to Present Clinical Development Update and Upcoming Catalysts at Life Sciences Future 2026 Conference

Newsfile Corp · 23 Sept 2026neutral

Phio Pharmaceuticals announced it will present at the Life Sciences Future 2026 Conference on September 30 to October 1, 2026, in King of Prussia, Pennsylvania. CEO Robert Bitterman will provide an update on the completed Phase 1b clinical study of PH-762 in cutaneous squamous cell carcinoma and outline planned next steps to advance the program.

Why it matters — PHIO watchers would care because the presentation provides an update on the completed Phase 1b study of its lead candidate PH-762 and signals the program's path toward its next stage of clinical development.

Phio Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

Newsfile Corp · 11 Sept 2026positive

Phio Pharmaceuticals announced that members of its management team will be available for one-on-one investor meetings at the H.C. Wainwright 28th Annual Global Investment Conference, held September 14-16, 2026, at the Lotte New York Palace Hotel in New York City. The company said management will highlight progress and future development plans for its INTASYL siRNA gene-silencing therapeutic PH-762.

Why it matters — The conference participation gives PHIO watchers an opportunity to hear directly from management about the company's progress and development plans for PH-762, its lead clinical-stage candidate.

Phio Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update

Newsfile Corp · 6 Aug 2026positive

Phio Pharmaceuticals reported its financial results for the quarter ended June 30, 2026, and provided a business update. The company highlighted strategic milestone advancements for its lead clinical candidate PH-762, including initiation of commercial scale API production, long-term non-clinical toxicology work, completion of Phase 1b pharmacology, and new intellectual property announcements.

Why it matters — A PHIO watcher would care because these milestones mark progress for its lead clinical candidate PH-762 toward commercialization-readiness and the expansion of its intellectual property position.

FAQ

Frequently asked questions about PHIO stock

What is the PHIO stock price forecast for 2026-2027?

The 1 Wall Street analysts covering Phio Pharmaceuticals Corp. have a median 12-month price target of $14, with estimates ranging from $14 to $14. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is PHIO stock a buy right now?

Of the 1 analysts covering Phio Pharmaceuticals Corp., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Phio Pharmaceuticals Corp. 15 out of 100 across roughly 4,600 US stocks as at 13 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank PHIO?

As at 13 Oct 2026, Phio Pharmaceuticals Corp. ranks 15 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (91 of 100).

Will PHIO stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +1398.1% from the last close, and Ticker Nerd's factor model ranks Phio Pharmaceuticals Corp. 15 out of 100 as at 13 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the PHIO stock forecast for 2030?

No analyst covering Phio Pharmaceuticals Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PHIO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $14 to $14 over the next 12 months.

How has PHIO stock performed over the past year?

Phio Pharmaceuticals Corp. returned -57.1% over the 12 months to 13 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Phio Pharmaceuticals Corp. do?

Phio Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company focused on developing immuno-oncology therapeutics using its proprietary INTASYL RNA interference platform.

What is the latest news on PHIO?

The most recent item we track (Newsfile Corp, 5 Oct 2026): "Phio Pharmaceuticals to Present at the National Investment Banking Association (NIBA) 153rd Conference". Phio Pharmaceuticals announced it will present at the National Investment Banking Association's 153rd Conference on October 6-7, 2026, in Fort Lauderdale, Florida. CEO Robert Bitterman will present the company's INTASYL siRNA therapeutic platform, its differentiated delivery approach, and its strategic direction, including a development update on the lead PH-762 program in cutaneous squamous cell carcinoma.

Company

About Phio Pharmaceuticals Corp.

Phio Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company focused on developing immuno-oncology therapeutics using its proprietary INTASYL RNA interference platform. The company’s current work centers on gene-silencing candidates designed to help immune cells better recognize and attack tumor cells, with a primary emphasis on cancer research and treatment applications. Its lead programs include PH-762, which targets PD-1 expression in ongoing clinical studies, and PH-894, which is being evaluated in preclinical research for selective BRD4 silencing. Phio Pharmaceuticals Corp. operates in the biotechnology sector and plays a role in advancing RNAi-based approaches for oncology, particularly in areas such as skin cancers and other solid tumors.

CEO Mr. Robert J. Bitterman · 6 employees · United States · https://phiopharma.com